Stress (2)
Referenties
1. Davydov M, Krikorian AD: Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. (Araliaceae) as an adaptogen: a closer look; J Ethnopharmacol 72:345-393, 2000.
2. Grandhi A, Mujumdar AM, Patwardhan B: A comparative pharmacological investigation of ashwagandha and ginseng; J Ethnopharmacol 44:131-135, 1994.
3. Archana R, Namasivayam A: Antistressor effect of Withania somnifera; J Ethnopharmacol 64:91-93, 1999.
4. Dhuley JN: Effect of ashwagandha on lipid peroxidation in stress-induced animals; J Ethnopharmacol 60:173-178, 1998.
5. Elsakka M, Pavelescu M, Grigorescu E: Withania somnifera, a plant with a great therapeutical future; Rev Med Chir Soc Med Nat Iasi 93:349-350, 1989.
6. Gupta GL, Rana AC: Protective effect of Withania somnifera Dunal root extract against protracted social isolation induced behavior in rats; Indian J Physiol Pharmacol 51:345-353, 2007.
7. Bhattacharya SK, Muruganandam AV: Adaptogenic activity of Withania somnifera: an experimental study using a rat model of chronic stress; Pharmacol Biochem Behav 75:547-555, 2003.
8. Stancheva SL, Mosharrof A: Effect of the extract of Rhodiola rosea L. on the content of the brain biogenic monamines; Med Physiol 40:85-87, 1987.
9. Maslova LV et al: The cardioprotective and antiadrenergic activity of an extract of Rhodiola rosea in stress; Eksp Klin Farmakol 57:61-63, 1994.
10. Lishmanov IB et al: Plasma beta-endorphin and stress hormones in stress and adaptation; Biull Eksp Biol Med 103:422- 424, 1987.
11. Lishmanov IB et al: The anti-arrhythmia effect of Rhodiola rosea and its possible mechanism; Biull Eksp Biol Med 116:175-176, 1993.
12. Maimeskulova LA et al: The participation of the mu-, delta- and kappa-opioid receptors in the realization of the antiarrhythmia effect of Rhodiola rosea; Eksp Klin Farmakol 60:38-39, 1997.
13. Lishmanov IB et al: Contribution of the opioid system to realization of inotropic effects of Rhodiola rosea extracts in ischemic and reperfusion heart damage in vitro; Eksp Klin Farmakol 60:34-36, 1997.
14. Bystritsky A, Kerwin L, Feusner JD: A pilotstudy of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD); J Altern Complement Med 14:175-180, 2008.
15. Olsson EM, von Scheele B, Panossian AG: A randomised, double-blind, placebo-controlled, parallelgroup study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue; Planta Med 2009.
16. Darbinyan V et al: Rhodiola rosea in stress induced fatigue – a double blind crossover study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty; Phytomedicine 7:365-371, 2000.
17. Spasov AA et al: A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen; Phytomedicine 7:85-89, 2000.
18. Fahey TD, Pearl MS: The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining; Biol Sport 15:135-144, 1998.
19: Monteleone P et al. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans; Neuroendocrinology 52:243-248, 1990.
20. Monteleone P et al: Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamopituitary-adrenal axis in healthy men; Eur J Clin Pharmacol 42:385-388, 1992.
21. Hellhammer J et al: Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress; Stress 7:119-126, 2004.
22. Delarue J et al: Fish oil prevents the adrenal activation elicited by mental stress in healthy men; Diabetes Metab 29:289-295, 2003.
23. Hamazaki K et al: Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial; Nutrition 21:705-710, 2005.
24. Hamazaki T et al: Antistress effects of DHA; Biofactors 13:41-45, 2000.
25. Bouic PJ et al: The effects of ß-sitosterol (BSS) and ß-sitosterol glucoside (BSSG) mixture on selected immune parameters of marathon runners: inhibition of post marathon immune suppression and inflammation; Int J Sports Med 20:258-262, 1999.
26. Ohmori H, Yamauchi T, Yamamoto I: Augmentation of the antibody response by lipoic acid in mice. II. Restoration of the antibody response in immunosuppressed mice; Jpn J Pharmacol 42:275-280, 1986.
27. Fomichev VI, Pchelintsev VP: The neurohumoral systems of patients with ischemic heart disease and under emotional-pain stress: the means for their pharmacological regulation; Kardiologiia 33:15-18, 1993. [Article in Russian]
28. Yokogoshi H et al: Effect of theanine, R-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats; Neurochem Res 23:667-673, 1998.
29. Yamada T et al: Theanine, gamma-glutamylethylamide, a unique amino acid in tea leaves, modulates neurotransmitter concentrations in the brain striatum interstitium in conscious rats; Amino Acids 36:21-27, 2009.
30. Ito K et al: Effects of L-theanine on the release of alpha-brain waves in human volunteers; Nippon Nogeikagaku Kaishi 72:153-157, 1998.
31. Nobre AC, Rao A, Owen GN: L-theanine, a natural constituent in tea, and its effect on mental state; Asia Pac J Clin Nutr 17:167-168, 2008.
32. Stough C et al: The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects; Psychopharmacology (Berl) 156:481-484, 2001.
33. Calabrese C et al: Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial; J Altern Complement Med 14:707-713, 2008.
34. Weiss RF, Fintelmann V: Herbal Medicine, 2nd ed; 262-263, Thieme, Stuttgart, Germany, 2000.
35. Houghton PJ: The scientific basis for the reputed activity of valerian; J Pharm Pharmacol 51:505-512, 1999.
36. Neuhaus W et al: Transport of a GABAA receptor modulator and its derivatives from Valeriana officinalis L. s. I. across an in vitro cell culture model of the blood-brain barrier; Planta Med 74:1338-1344, 2008.
37. Cavadas C et al: In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain; Arzneimittelforschung 45:753-755, 1995.
38. Ortiz JG, Nieves-Natal J, Chavez P: Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release; Neurochem Res 24:1373-1378, 1999.
39. Leathwood PD, Chauffard F: Aqueous extract of valerian reduces latency to fall asleep in man; Planta Med 51:144-148, 1985.
40. Leathwood PD et al: Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man; Pharmacol Biochem Behav 17:65-71, 1982.
41. Trevena L: Sleepless in Sydney – is valerian an effective alternative to benzodiazepines in the treatment of insomnia?; ACP J Club 141:A14-A16, 2004.
42. Ziegler G et al: Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia – a randomized, double-blind, comparative clinical study; Eur J Med Res 7:480-486, 2002.
43. Nemeroff CB: The role of GABA in the pathophysiology and treatment of anxiety disorders; Psychopharmacol Bull 37:133-146, 2003.
44. Kendell SF, Krystal JH, Sanacora G: GABA and glutamate systems as therapeutic targets in depression and mood disorders; Expert Opin Ther Targets 9:153-168, 2005.
45. Abdou AM et al: Relaxation and immunity enhancement effects of gamma aminobutyric acid (GABA) administration in humans; Biofactors 26:201-208, 2006.
46. Van Praag HM, Lemus C: Monoamine precursors in the treatment of psychiatric disorders, In: Nutrition and the Brain (Wurtman RJ, Wurtman JJ, eds.); 89-139, Raven Press, New York, USA, 1986.
47. Den Boer JA, Westenberg HG: Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder; Psychiatry Res 31:267-278, 1990.
48. Chadwick D et al: Manipulation of brain serotonin in the treatment of myoclonus; Lancet 2:434-435, 1975.
49. Schruers K et al: Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients; Psychiatry Res 113:237-243, 2002.
50. Bos, C: Melatonine: Chronobiologische waakhond met onvermoede mogelijkheden (1); TvOG 2(25):4-11, 2010.
51. Bos, C: Melatonine: Chronobiologische waakhond met onvermoede mogelijkheden (2); TvOG 3(25):41-45, 2010.
52. Bos, C: Melatonine: Chronobiologische waakhond met onvermoede mogelijkheden (3); TvOG 4(25):52-56, 2010.
53. Owasoyo JO, Neri DF, Lamberth JG: Tyrosine and its potential use as a countermeasure to performance decrement in military sustained operations; Aviat Space Environ Med 63:364-369, 1992.
54. Salter CA: Dietary tyrosine as an aid to stress resistance among troops; Mil Med 154:144-146, 1989.
55. Deijen JB et al: Tyrosine improves cognitive performance and reduces blood pressure in cadets after one week of a combat training course; Brain Res Bull 48:203-209, 1999.
56. Vinogradov VV et al: Thiamine prevention of the corticosteroid reaction after surgery; Probl Endokrinol (Mosk) 27:11-16, 1981. [Article in Russian]
57. Onuki M, Suzawa A: Effect of pantethine on the function of the adrenal cortex. 2. Clinical experience using pantethine in cases under steroid hormone treatment; Horumon To Rinsho 18:937-940, 1970. [Article in Japanese]
59. Honma K et al: Effects of vitamin B12 on plasma melatonin rhythm in humans: increased light sensitivity phase-advances the circadian clock?; Experientia 48:716-720, 1992.
60. Hashimoto S et al: Vitamin B12 enhances the phase-response of circadian melatonin rhythm to a single bright light exposure in humans; Neurosci Lett 220:129-13, 1996.
58. Groff JL, Gropper SS, Hunt SM: ‘Advanced Nutrition and Metabolism’; Brooks Cole, Pacific Grove, Cal. (USA), 1999. ISBN-10 0534555217.
61. Tomoda A, Miike T, Matsukura M: Circadian rhythm abnormalities in adrenoleukodystrophy and methyl B12 treatment; Brain Dev 17:428-431, 1995.
62. Heller R et al: L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin; J Biol Chem 276:40-47, 2001.
63. Nakai K et al: Ascorbate enhances iNOS activity by increasing tetrahydrobiopterin in RAW 264.7 cells; Free Radic Biol Med 35:929-937, 2003.
64. Gromova EG et al: Regulation of the indices of neuroendocrine status in surgical patients with lung cancer using optimal doses of ascorbic acid; Anesteziol Reanimatol 5:71-74, 1990.